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ABSTRACT
Objective: We studied the reciprocal effect of pregnancy and von Hippel-Lindau (VHL) disease by
analyzing the influence of pregnancy on VHL disease-related lesions and VHL disease on preg-
nancy outcome.
Methods: Medical charts and imaging reports from the VHL disease expertise centers in the
Netherlands were used to retrospectively assess lesion progression score before and after
pregnancy and to obtain data on pregnancy outcome and VHL disease-related lesions. The
Friedman test was used for analysis (p  0.05). Twenty-nine patients were studied (48 preg-
nancies, 49 newborns).
Results: The progression score of cerebellar hemangioblastomas significantly changed between the
singleMRI scan before and the2 scans after pregnancy (p0.049) (n12). Fetalmortality ratewas
2% (n  1) caused by maternal pheochromocytoma. Maternal VHL disease-related complications
occurred in 17% (n8) of all pregnancies. In 4 patients, a life-threatening situation emerged: hydro-
cephalus due to cerebellar hemangioblastoma (n2) and pheochromocytoma (n2).
Conclusions: Pregnancy in patients with VHL disease induces cerebellar hemangioblastoma pro-
gression and causes a high VHL disease-related pregnancy complication rate. We recommend
intensified surveillance of patients with VHL disease, especially of cerebellar hemangioblastomas
during preconception care and pregnancy. Neurology® 2012;79:793–796
GLOSSARY
RCC renal cell carcinoma; VHL Von Hippel-Lindau.
Von Hippel-Lindau (VHL) disease is inheritable and associated with the development of mul-
tiple well-vascularized tumors throughout life. The onset of disease occurs at a mean age of 26
years (range 1–70 years).1 Hemangioblastomas are frequently found during adolescence, devel-
oping in the retina, cerebellum, spinal cord, supratentorial region, and brainstem. In the
visceral organs, pheochromocytomas, renal cell carcinoma (RCC) and renal cysts, pancreatic
islet cell tumors, and cysts occur.1 International guidelines recommend intensive surveillance to
detect tumors in an early stage.1 Although triggers for VHL disease tumor progression are
unknown, cerebellar hemangioblastomas are reported to oscillate between periods of growth
and stability.2 In addition, several case studies show that pregnancy or delivery in patients with
VHL disease can be complicated by CNS hemangioblastoma or pheochromocytoma with
consequences for maternal and neonatal outcome.3–6 One retrospective study based on a ques-
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tionnaire from 30 patients with VHL disease
described a 5% self-reported VHL-related
maternal morbidity.7 Progression of VHL le-
sions during pregnancy could be explained by
several factors. A rise in venous pressure by in-
creased circulating blood volume and compres-
sion of the vena cava inferior to the growing
uterus could be responsible for growth of he-
mangioblastomas. In addition, estrogen-
induced endothelial proliferation is thought to
stimulate stromal hemangioblastoma cell
growth, and progesteronemay increase venous dis-
tensibility. Placental-derived angiogenic factors
might add to hemangioblastoma growth be-
cause proangiogenic factors are present in the
maternal circulation.8
We aimed to study the reciprocal effect of
pregnancy and VHL disease by analyzing the
influence of pregnancy on VHL disease-related
lesions and of VHL disease on pregnancy
outcome.
METHODS Subjects. We retrospectively studied 29 of 31
women with VHL disease who were receiving surveillance in
VHL disease expertise centers in the Netherlands. The surveil-
lance includes funduscopy, MRI of the spinal cord and cerebel-
lum, CT scan or ultrasound of the abdomen, and determination
of plasma and urine levels of metanephrines.1 Diagnosis of VHL
disease was based on clinical criteria or confirmed by germline
mutation testing. Clinical criteria were met by either a positive
family history of VHL disease with a personal history of at least
one CNS hemangioblastoma, a case of RCC, or one pheochro-
mocytoma or a personal history of 2 or more CNS hemangio-
blastomas or one CNS hemangioblastoma with a VHL
disease-associated visceral lesion.1,9
Measurements. The influence of VHL disease on pregnancy-
related outcome and the influence of pregnancy on VHL disease
activity were scored using the following parameters: 1) VHL
disease-related complaints, number of VHL disease-related in-
terventions, and size and number of individual VHL lesions; and
2) pregnancy-related fetal and maternal mortality and morbidity,
VHL disease-associated and VHL disease-unrelated (e.g.,
pregnancy-related hypertensive disorders).
Data concerning VHL lesions leading to interventions or
complaints before, during, and after pregnancy of all patients
were extracted from medical records and completed by tele-
phone interview or during outpatient clinic visits.
Data on all interventions performed within 4 years before
and 4 years after pregnancy were collected. The severity of com-
plaints before, during, and after pregnancy was subjectively
scored as follows: 1 (no complaints), 2 (stable), 3 (progressive),
and 4 (loss of function). Imaging reports (MRI scan, CT scan,
ultrasound, or funduscopy), available for 15 pregnancies, were
used to assess the effect of pregnancy on individual lesions in the
cerebellum, spinal cord, retina, kidney, and pancreas. One or 2
measurements before and 1 or 2 measurements after pregnancy
were collected with a maximum time span ranging from 4 years
before the last menstruation until 4 years after delivery. Organ
involvement was scored with a lesion progression score as fol-
lows: 1 (no lesions), 2 (stable), 3 (progression in number or size),
or 4 (progression in number 2 or 2 cm in size, for retinal
lesions threatened vision). The score 5 was noted when CNS and
retinal lesions caused a life-threatening situation or blindness.
Pheochromocytomas were scored as absent or present. In this
design, patients served as their own control.
Standard protocol approvals, registrations, and patient
consents. Patient identity was protected by unique patient
identifiers; codes were known only to 2 database managers. Ac-
cording to Dutch law no further institutional review board ap-
proval was required. All subjects provided written informed
consent to participate in the study.
Statistical analysis. Statistical analysis was performed by the
Friedman test (p  0.05).
RESULTS All 31 patients with VHL disease with at
least one delivery known in the VHL disease centers
were approached between April and September
2010. Two patients were excluded for personal and
cognitive reasons, resulting in 29 patients and 48
pregnancies with 49 newborns (table 1). The women
delivered between 1966 and 2010; 60% delivered af-
ter 1990.
Table 1 Demographics of the patients
and pregnancies
Characteristic Value
Patients with VHL disease, n 29
Pregnancies, n 56
Vital pregnancies (>24weeks), n 48
Age at first pregnancy, y, mean (SD) 26.9 (5.5)
VHL disease known during first pregnancy
(n  29), n (%)
Positive 12 (41)
Negative 17 (59)
VHL disease known during pregnancy, n (%)
Positive 20 (42)
Negative 28 (58)
Age at diagnosis for those known to have
VHL disease during first pregnancy, y
22
Clinical VHL diseasemanifestations
before first pregnancy (n  29), n (%)
CNS
Angioma retina 7 (24)
Hemangioblastoma cerebellum 7 (24)
Hemangioblastoma spinal cord 2 (7)
Visceral lesions
Pheochromocytoma 2 (7)
Renal cysts 3 (10)
Renal cell carcinoma 2 (7)
Pancreatic cysts 4 (14)
Pancreatic neuroendocrine tumor 0 (0)
Abbreviation: VHL von Hippel-Lindau.
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Maternal VHL disease-related complications oc-
curred in 17% (n 8) of all pregnancies (table 2); in
half of the women VHL disease was diagnosed before
their pregnancy. In those 8 pregnancies, 10 VHL le-
sions led to new or increased complaints or interven-
tion: hemangioblastoma cerebellum (n  2) and
spinal cord (n  1), pheochromocytoma (n  2),
RCC (n  1), and retinal angioma (n  4, 3 of
which with major impaired vision loss/ablation). In 4
patients, a life-threatening situation emerged: cere-
bellar hemangioblastoma (n  2) and pheochromo-
cytoma (n  2) (figure), resulting in 1 fetal death
and 2 premature deliveries by cesarean section. All
VHL disease complications occurred during a first
pregnancy; 7 of these 8 patients did not pursue an-
other pregnancy. Of the patients without a VHL dis-
ease complication, 67% had another pregnancy. The
severity of VHL disease-related patient complaints
during pregnancy (n  48) was significantly in-
creased (p 0.005). VHL disease interventions dur-
ing pregnancy (n  7) and in the first year after
delivery (n  8) were more frequent than those in
the 4 years before pregnancy (average n  3).
Imaging-based progression scores of VHL dis-
ease-related lesions showed in the cerebellum a signif-
icant change of progression in the period between 1
MRI scan before and 2 MRI scans after pregnancy
(p  0.049). An increase in the progression score in





(yes/no) Lesion Complaints Intervention
1 No Bilateral pheochromocytoma
(revealed after delivery)
None Bilateral adrenalectomy
(6 mo after delivery)
2 No Bilateral pheochromocytoma Nausea, headache, sweating,
abdominal pain
Cesarean section combined
with adrenalectomy (28 wk of
gestation)





with craniotomy (35 wk of
gestation)
Retinal angioma None Eye laser treatment (22 wk of
gestation)
4 No Cerebellar hemangioblastoma
and hydrocephalus
Headache, vomiting; later on
balance disturbance, speech
disorder, muscle weakness
Craniotomy (1 wk after
delivery)
5 Yes Spinal cord hemangioblastoma Radiating lower back pain Resection hemangioblastoma
(6 mo after delivery)
6 Yes Renal cell carcinoma None Partial nephrectomy right-
sided (20 wk of gestation)
Ablatio retinae Vision loss to 10% Vitrectomy (10 wk of
gestation)
7 No Ablatio retinae: papillary angioma
(known before pregnancy)
Visual field loss None
8 Yes Ablatio retinae: angioma (known
before pregnancy)
Total vision loss None
Figure MRI cerebellum, cerebellar hemangioblastoma, and hydrocephalus complicating pregnancy
(A, B) Lesion on the right side of the cerebellum 3 months before pregnancy, during a routine VHL disease screening,
measuring 0.5 cm (with gadolinium). (C) The same lesion at 32 weeks of gestation on the right side of the cerebellum,
measuring a central component of 2.7 cm with a cystic component of 4 cm (table 2, patient 3).
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the first measurement early after pregnancy has been
measured at a mean of 6.4 months after delivery and
can be considered as an effect of pregnancy. A de-
crease in progression score was found in the second
MRI scan after pregnancy 1 year later (mean 18.7
months after delivery). In other organs, no signifi-
cant progression of lesions was found.
Maternal mortality rate was 0%; fetal death oc-
curred in one patient (2%) at a gestational age of 32
weeks, caused by maternal hypertension from pheo-
chromocytoma. Maternal pregnancy-related compli-
cations occurred in 15% of pregnancies (n  7);
pregnancy-related hypertensive disorders were seen
in 12.5% of patients (n  6), and one patient has
intrahepatic cholestasis of pregnancy.
DISCUSSION Increased activity of VHL disease,
in particular of cerebellar hemangioblastomas, was
observed in pregnancy. In 17% of patients, VHL
disease-related complications were observed; VHL
disease was diagnosed in only half of the patients
before pregnancy. Four of 8 complicated pregnan-
cies resulted in a life-threatening situation for
mother and child (with one fetal death). Previ-
ously a VHL disease-related morbidity during
pregnancy of 5.4% was found.7 However, these
data were derived from a written questionnaire
sent to patients randomly. In our study, data were
derived from medical reports, and all mothers with
the diagnosis of VHL disease in the Dutch VHL
disease expertise centers were evaluated.
Our result of cerebellar hemangioblastoma pro-
gression during pregnancy is in line with preliminary
data showing a significantly higher complication rate
for hemangioblastomas in patients with VHL disease
with at least one pregnancy.10 Possible explanations
are the hormonal (growth factors and estrogen) and
hemodynamic changes occurring during pregnancy,
adding to the preexisting increased vascular endothe-
lial growth factor expression (a direct downstream
effect of biallelic VHL gene inactivation).8 Therefore,
a direct relationship between pregnancy and progres-
sion of cerebellar hemangioblastomas is likely. VHL
disease-related lesions in other organs showed no sig-
nificant change in progression score after pregnancy.
This finding may be explained by the few patients
with specific lesions and the age at onset of other
VHL disease manifestations. In addition, the retro-
spective setting and the small sample size limit this
study. However, larger series in this rare disease are
difficult to achieve.
Our results show growth of VHL cerebellar he-
mangioblastomas during pregnancy and a high VHL
disease complication rate during pregnancy. Intensi-
fied surveillance of patients with VHL disease is rec-
ommended in a specialized medical center during
preconception care and pregnancy. We recommend
MRI of the cerebellum at 4 months of gestation and
before delivery.
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